Eevia Secures Repeat Sales Order Worth KSEK 990 (KEUR 91), with Potential Upside

Eevia Health Plc (”Eevia” or ”The Company”) has received a repeat sales order for KEUR 91 (KSEK 990) from a large international ingredient company for Feno-Myrtillus® 25 organic (bilberry extracts), with the possibility of an additional KSEK 825 (KEUR 76).

Eevia is pleased to announce that it has received a repeat sales order worth KEUR 91 (KSEK 990) from a leading international nutraceutical ingredient company for its premium organic bilberry extract, Feno-Myrtillus® 25. Additionally, the customer has indicated a potential follow-up order worth KEUR 76 (KSEK 825) shortly.

The customer, a globally recognized supplier of nutraceutical ingredients operating across three continents, first partnered with Eevia in the summer of 2024. This repeat order underscores Eevia's ability to deliver high-quality, organic ingredients while competing with established industry players.

“This is a sophisticated customer with high standards, and securing this repeat order is a testament to the quality and reliability of our products,” says Stein Ulve, CEO of Eevia Health. “Moreover, this order contributes to achieving our financial turnaround targets for the first quarter of 2025—an important milestone for our team.”

Eevia Health is committed to providing sustainable, organic, bioactive ingredients to support global health and wellness. The Company looks forward to further strengthening its relationship with this key customer and expanding its market presence.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc

Email: stein.ulve@eeviahealth.comor investor@eeviahealth.com

Telephone: +358400 22 5967

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.

Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

As a pioneering company, Eevia is developing high-value food ingredients, blended solutions, and biomaterials that significantly benefit human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.